The rapidly evolving landscape of HCC: Selecting the optimal systemic therapy

Area of Science:

• Hepatocellular Carcinoma Research
• Medical Oncology
• Immunotherapy

Background:

• Advanced hepatocellular carcinoma (HCC) treatment has seen significant progress.
• Overall survival rates have improved, particularly for patients with sensitive tumors and good liver function.
• The treatment landscape is evolving with new first-line agents and immune checkpoint inhibitor-based therapies.

Purpose of the Study:

• To review the advancements in systemic treatment options for advanced HCC.
• To discuss the current standards of care and emerging therapies.
• To highlight the complexities in selecting optimal treatment strategies.

Main Methods:

• Review of recent clinical practice guidelines and landmark trials in advanced HCC.
• Analysis of efficacy and safety data for current first-line therapies.
• Discussion of patient-specific factors influencing treatment selection.

Main Results:

• Atezolizumab plus bevacizumab and durvalumab plus tremelimumab are now standard of care, surpassing older agents like sorafenib and lenvatinib.
• Treatment decisions are patient-driven, integrating efficacy, comorbidities, liver function, and safety profiles.
• Predictive biomarkers for patient stratification are still under development.

Conclusions:

• The systemic treatment of advanced HCC has expanded significantly, offering improved outcomes.
• Personalized treatment selection is crucial due to the lack of head-to-head comparisons among all options.
• The complexity of treatment algorithms is increasing as therapies move to earlier disease stages.